Fremantle Dermatology | Fremantle, Australia
Status and phase
Conditions
Treatments
About
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects are eligible to be included in the study only if all of the following criteria apply:
Subjects with a chronic moderate to severe plaque-type psoriasis for at least 6 months (as determined by subject interview and confirmation of diagnosis through physical examination by Investigator).
Subjects must have moderate to severe nail psoriasis at Screening and Baseline, defined by:
Subjects must have moderate to severe plaque psoriasis at Screening and Baseline, defined by:
Subjects must be considered candidates for systemic therapy, meaning psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.
Exclusion criteria
Subjects are excluded from the study if any of the following criteria apply:
Primary purpose
Allocation
Interventional model
Masking
99 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Head, Clinical development
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal